

***In the Claims:***

Please cancel claims 1-38, 40, and 43-47 without prejudice or disclaimer.

Please substitute the following claim 39 for the pending claim 39:

39.(Once amended) A method of stimulating cell division which comprises:

(A) contacting cells with an effective amount of one or more muteins of a human basic fibroblast growth factor, or biologically active peptides thereof *in vitro*, wherein said one or more muteins comprise the substitution of a neutral and/or hydrophobic amino acid for one or more of the following:

- (a) Glutamate 89; or
- (b) Aspartate 101; or
- (c) Leucine 137;

wherein the numbering of amino acids is based on SEQ ID NO:1; or

(B) contacting cells with an effective amount of said one or more muteins, or biologically active peptides thereof *in vivo*.

Please substitute the following claim 41 for the pending claim 41:

41. (Once amended) A method of healing a wound comprising contacting said wound with an effective amount of one or more muteins of a human basic fibroblast growth factor, or biologically active peptides thereof, wherein said one or more muteins comprise the substitution of a neutral and/or hydrophobic amino acid for one or more of the following:

- (a) Glutamate 89; or
- (b) Aspartate 101; or

(c) Leucine 137;

wherein the numbering of amino acids is based on SEQ ID NO:1.

Please substitute the following claim 42 for the pending claim 42:

42. (Once amended) A method of treating ischemia, peripheral vascular disease, a neural injury, a gastric ulcer, a duodenal ulcer, or heart disease comprising contacting cells with an effective amount one or more muteins of a human basic fibroblast growth factor, or biologically active peptides thereof, wherein said one or more muteins comprise the substitution of a neutral and/or hydrophobic amino acid for one or more of the following:

(a) Glutamate 89; or

(b) Aspartate 101; or

(c) Leucine 137;

wherein the numbering of amino acids is based on SEQ ID NO:1.

Please enter the following new claims 48-75:

48. (New) The method of claim 42, wherein ischemia is treated.

49. (New) The method of claim 42, wherein peripheral vascular disease is treated.

50. (New) The method of claim 42, wherein a neural injury is treated.

51. (New) The method of claim 42, wherein a gastric ulcer is treated.

52. (New) The method of claim 42, wherein a duodenal ulcer is treated.

53. (New) The method of claim 42, wherein heart disease is treated.

54. (New) The method of any one of claims 39, 41 or 42, wherein said one or more muteins comprise the substitution of a hydrophobic amino acid for Glu<sup>89</sup>.

55. (New) The method of any one of claims 39, 41 or 42, wherein said one or more muteins comprise the substitution of a hydrophobic amino acid for Asp<sup>101</sup>.

56. (New) The method of any one of claims 39, 41 or 42, wherein said one or more muteins comprise the substitution of a hydrophobic amino acid for Leu<sup>137</sup>.

57. (New) The method of any one of claims 39, 41 or 42, wherein said one or more muteins comprise the substitution of a neutral amino acid for Glu<sup>89</sup>.

58. (New) The method of any one of claims 39, 41 or 42, wherein said one or more muteins comprise the substitution of a neutral amino acid for Asp<sup>101</sup>.

59. (New) The method of any one of claims 39, 41 or 42, wherein said one or more muteins comprise the substitution of a neutral amino acid for Leu<sup>137</sup>.

60. (New) The method of any one of claims 39, 41 or 42, wherein said neutral amino acid is defined as alanine and said hydrophobic amino acid is defined as tyrosine.

61. (New) The method of any of claims 39, 41 or 42, wherein said one or more muteins of human basic fibroblast growth factor, or biologically active peptides thereof, comprise one or more of the following substitutions:

- (a) substitution of Glutamate 89 with alanine or tyrosine;
- (b) substitution of Aspartate 101 with alanine; or
- (c) substitution of Leucine 137 with alanine;

or any combination thereof, wherein the numbering of amino acids is based on SEQ ID NO:1.

/

/



A8  
Cord.

74. (New) The method of any one of claims 39, 41 or 42, wherein said mutein

75. (New) The method of claim 39, wherein said method comprises contacting

cells *in vivo*.

Year	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	